Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Acq. announced
Inv. presentation
|
|
Mirum Pharmaceuticals, Inc. (MIRM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 10/13/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Radovich Peter (COO) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Sold 1,425 shares
@ $25.6466, valued at
$36.5k
|
|
| 07/05/2023 |
4
| Longpre Lara (Chief Development Officer) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Sold 1,004 shares
@ $25.6466, valued at
$25.7k
|
|
| 07/05/2023 |
4
| Vig Pamela (Head of Research & Development) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Sold 1,425 shares
@ $25.6466, valued at
$36.5k
|
|
| 07/05/2023 |
4
| Howe Jolanda (SVP, Global Controller) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Sold 915 shares
@ $25.6466, valued at
$23.5k
Exercised 1,563 options to buy
@ $0
Exercised 1,042 restricted stock units
@ $0 |
|
| 07/05/2023 |
4
| Peetz Christopher (President and CEO) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Sold 5,498 shares
@ $25.6466, valued at
$141k
|
|
| 06/09/2023 |
4
| GREY MICHAEL G (Director) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Sold 14,608 shares
@ $29, valued at
$423.6k
Exercised 14,608 options to buy
@ $2.936, valued at
$42.9k
|
|
| 06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
4
| Radovich Peter (COO) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Granted 968 shares
@ $16.9235, valued at
$16.4k
|
|
| 05/19/2023 |
4
| Longpre Lara (Chief Development Officer) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Granted 684 shares
@ $16.9235, valued at
$11.6k
|
|
| 05/19/2023 |
4
| Vig Pamela (Head of Research & Development) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Granted 684 shares
@ $16.9235, valued at
$11.6k
|
|
| 05/19/2023 |
4
| Peetz Christopher (President and CEO) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Granted 1,256 shares
@ $16.9235, valued at
$21.3k
|
|
| 05/09/2023 |
3
| Howe Jolanda (SVP, Global Controller) has filed a Form 3 on Mirum Pharmaceuticals, Inc. |
| 05/04/2023 |
4
| GREY MICHAEL G (Director) has filed a Form 4 on Mirum Pharmaceuticals, Inc.|
Txns:
| Sold 14,608 shares
@ $28, valued at
$409k
Exercised 14,608 options to buy
@ $2.936, valued at
$42.9k
|
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/03/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Mirum Pharmaceuticals, Inc. |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 03/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/08/2023 |
8-K
| Quarterly results |
| 03/08/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.6% stake in Mirum Pharmaceuticals, Inc |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.9% stake in Mirum Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G
| EVENTIDE ASSET MANAGEMENT, LLC reports a 5.6% stake in Mirum Pharmaceuticals, Inc. |
|
|
|